3P Biovian and Rokote Laboratories will make a vaccine against Covid-19

3P is permanent has signed an agreement with Vaccine laboratories to make a new vaccine against it Covid 19 based on adenovirus vectors. In particular, the Navarrese company will provide both the active substance and the pharmaceutical product to the Finnish company to “bring the FINCoVac 2.1 intranasal vaccine to Phase I clinical studies.”

As reported by the first this Thursday, the vaccine aims to “stimulate a strong mucosal immune response in nasopharyngeal cells, which are the main point of entry for SARS-CoV-2, which causes Covid- 19. ” Such mucosal immunity “could prevent both the infection and the spread of this pathology.”

Rokote Laboratories specializes in advanced vaccine technologies. In particular, it focuses on intranasal vaccines that stimulate mucosal immunity. Using advanced adenoviral vector technologies, his goal is to “improve the efficacy and safety of vaccines.” In response to the Covid-19 pandemic, the company developed a “vaccine in a spark nasal as an easy-to-administer and non-invasive option, along with existing vaccines. ”

In this way, the agreement includes the GMP manufacturing of the Ad5 vector for Phase I clinical studies, using Biovian’s standard 3P process in its facilities located in Turks (Finland). Due to the “urgent needs” of Rokote Laboratories, the program has moved to GMP production “extremely fast,” benefiting from 3PBiovian’s extensive experience in adenovirus-based processes.

CONCERNED VALUES

“We are pleased to partner with 3P Biovian to produce our next generation intranasal Covid-19 vaccine. The ability to use the group’s standard process for rapid GMP batch production, combined with his extensive experience in adenovirus-based processes, made him an ideal partner. We hope together that we can continue to move forward in the development of vaccines in Finland,” he said this Thursday. Erkko FishingHead of Vaccine Laboratories.

For his part, Damaso MoleroCEO of 3PBiovian, appreciating the importance of this alliance: “We are delighted that Rokote Laboratories has chosen us as partners for the development of their innovative drug candidate based on adenovirus. The combination of 3P Biopharmaceuticals with Biovian allows us to provide therapeutic solutions in a wide spectrum and to address the manufacturing needs of high technological challenges such as this case. ”

A point that proved that Antti NieminenDeputy CEO of 3P Biovian: “Our company has two decades of experience in the development of viral vector processes and the manufacturing of adenoviruses according to GMP standards, and we are happy to participate in the journey of this new second generation vaccine today. the face of coronavirus. towards clinical trials.”